An African tree that crossed into the European laboratory
Yohimbe is a tree from the western strip of Africa—Cameroon, Equatorial Guinea, Gabon, Congo—where its bark has had an aphrodisiac reputation long before the word “pharmacology” existed. It was used in ceremonies, weddings, and celebrations, and was part of the region’s herbal knowledge.
Like so many other plants, its journey toward European science begins with colonial disdain and ends with laboratory curiosity. The powers that divided the continent in the 17th and 18th centuries often dismissed what local communities said about their remedies as superstition. Spanish expansion in what is now Equatorial Guinea, in the mid-19th century, brought back stories of a bark that local inhabitants called mbé. It was German sailors and chemists who, at the end of the 19th century, subjected the plant to analysis: in 1896, the responsible alkaloid, yohimbine, was isolated.
The first experiments with animals were striking: rodents treated with bark extract or pure yohimbine showed a notable increase in copulatory frequency. But, as often happens, the leap from the laboratory animal to the human being took decades to study with rigor.
What the evidence actually says
For much of the 20th century, yohimbine was the only plant-derived compound to which Western medicine truly granted the label of aphrodisiac. Studies published in journals such as Science (1984) or The Lancet (1987) described sexual responses in animals and clinical trials in humans; double-blind studies, later cited in Sexual and Marital Therapy (1989) and linked to centers like St. George’s Hospital in London, placed its efficacy against impotence of psychological origin at around 62% of cases.
It is important to read those figures in context. Yohimbine was once prescribed in France, Germany, the United Kingdom, and the United States for erectile dysfunction and lack of desire, and it still appears in classic medical handbooks. But the arrival of phosphodiesterase-5 inhibitors (the group including sildenafil and similar drugs) in the nineties displaced it almost completely from clinical practice: they were more effective, more predictable, and had a more manageable side-effect profile. Today, yohimbine is more a chapter in the history of sexual pharmacology than a first-line treatment.
Physiologically, yohimbine acts as an alpha-2 adrenergic receptor antagonist and raises norepinephrine levels, which stimulates circuits related to arousal. Hence its double-edged nature: the same mechanism that can promote erection and genital sensitivity is what makes it a general stimulant, sometimes compared to the amphetamine family, capable of accelerating the heart and triggering anxiety.
The problem is not pleasure, it is the heart
This is the real reason to treat yohimbe with respect. It is not so much that it “gets you high” as it is a cardiovascular stimulant with a narrow margin of safety. The literature itself records frequent adverse effects even at moderate doses: nausea, tachycardia, high blood pressure, dizziness, irritability, anxiety, and insomnia.
The contraindications are serious and do not allow for romantic nuances: anyone with hypertension, hypotension, cardiovascular, kidney, or stomach disease should avoid it, as should those with glaucoma, hypoglycemia, anxiety disorders, or states of hyperexcitability. Mixing it with alcohol, other stimulants (caffeine, amphetamines, cocaine), or certain medications can trigger blood pressure crises, respiratory distress, and arrhythmias. In short, it is a substance that interacts poorly with many things and is particularly poorly tolerated by an exhausted or medicated body.
A note on harm reduction: the yohimbine content in bark preparations is enormously variable and difficult to know in advance, which means that “the same amount” of plant does not mean the same dose. That unpredictability, added to its cardiovascular profile, is the reason why we do not describe preparation methods or consumption guidelines here. If someone is considering its use for health reasons, the place to discuss it is a doctor’s office, not a forum.
Stimulants do not agree with everyone
It is worth remembering an idea that physician Andrew Weil expressed clearly: stimulants do not produce universal euphoria. They leave many people restless, agitated, and unable to rest, and there are people so sensitive that a small amount is enough to prevent sleep for many hours. Yohimbine fits that pattern. Where one person finds pleasant stimulation, another will find only anxiety and palpitations. Learning to recognize what effect each substance produces in one’s own body—and accepting that the response is not the same for everyone—is part of any informed relationship with psychoactive substances.
Botany, names, and a tree in trouble
There is some taxonomic confusion surrounding yohimbe. The names Corynanthe yohimbe and Pausinystalia yohimbe have been used as synonyms, and there are related species—such as Corynanthe pachyceros or Pausinystalia macroceras—that are difficult to distinguish and have similar alkaloid profiles. Yohimbine (also called aphrodine, corynine, or quebrachine) coexists in the bark with other indole alkaloids of the same group.
It is a large, perennial tree that reaches about 10–15 meters (33–49 feet) and can significantly exceed that, with oval leaves and winged seeds of short viability. And it is, furthermore, a plant with a fragile future: the bark is only harvested from specimens of a certain age, and stripping the bark kills the tree. The pressure of growing global demand has been emptying the forests of Cameroon and pushing harvesting toward other areas, with large-scale cultivation attempts that do not fully resolve the conservation problem. This is not a minor detail: behind every “natural” extract is an ecosystem that pays the bill.
Yohimbe and the law in Spain
The legal status of yohimbe illustrates well how arbitrary the border between “medicine” and “drug” can be. Yohimbine hydrochloride was regulated as a medicine, available only in pharmacies. In Spain during the seventies, it became popular in party scenes—the famous “cachondina”—and ended up being withdrawn, while in other European countries it continued to be prescribed for erectile dysfunction. The bark, for its part, was removed from herbal shops following a ministerial order that, under the last Aznar government, restricted nearly two hundred plants, a measure that European health authorities themselves considered poorly substantiated in several cases.
Critical reading
The label of “the only aphrodisiac recognized by science” has more of a slogan than a rigorous statement today. It is true that yohimbine was, for decades, the plant compound with the most experimental support in this field; it is also true that its efficacy was always partial, its adverse effects notable, and that modern pharmacology has left it behind. A good portion of the references circulating about yohimbe come from popularizers of psychoactive culture—Christian Rätsch, Adam Gottlieb, Luis Otero, among others—and from old clinical trials; it is convenient to distinguish between verifiable clinical data and the ethnobotanical enthusiasm that often accompanies it. As with almost everything surrounding substances, informed skepticism protects more than fascination.
